Big pharma is out there looking especially as so many early stage failures burning up cash so no problems with getting in late still at massive discount. Meanwhile they can bleed them like BTA Aussie ones don't have enough decent coverage and comparison against peers in the research of them so hard for investors to work out if they represent value at different stages rather than localised interest and hype to get funding.
